Evidence map›Paper›PMID 26353857›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles.

Xinmeng Qi, Dan Yu, Bo Jia, Chunshun Jin, Xueshibojie Liu, Xue Zhao, Guangxin Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Present Scenario of Bioconjugates in Cancer Therapy: A Review.International journal of molecular sciences · 2019
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Tumor microenvironment - Unknown niche with powerful therapeutic potential.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xinmeng QiDepartment of Otolaryngology Head and Neck Surgery, the Second Hospital, Jilin University, Changchun, 130041, China.
Dan YuDepartment of Otolaryngology Head and Neck Surgery, the Second Hospital, Jilin University, Changchun, 130041, China. yudan19792003@163.com.
Bo JiaDepartment of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, 100021, China.
Chunshun JinDepartment of Otolaryngology Head and Neck Surgery, the Second Hospital, Jilin University, Changchun, 130041, China. chunshunjindan@163.com.
Xueshibojie LiuDepartment of Otolaryngology Head and Neck Surgery, the Second Hospital, Jilin University, Changchun, 130041, China.
Xue ZhaoDepartment of Otolaryngology Head and Neck Surgery, the Second Hospital, Jilin University, Changchun, 130041, China.
Guangxin ZhangDepartment of Thoracic Surgery, the Second Hospital, Jilin University, Changchun, 130041, China.
Second Affiliated Hospital of Jilin University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesoporous silica nanoparticles (MSNs) represent a new form of drug nanocarrier with thermo/pH-coupling sensitivity and site-specificity. CD133(+) Hep-2 laryngeal cancer cells are responsible for multidrug resistance due to elevated expression of ABCG2. Since positively charged nanoparticles could easily uptake nucleic acids, we examined the possibility of using this new drug delivery system to simultaneously deliver different chemotherapeutic drugs and siRNA targeting ABCG2. Our results demonstrated that both antitumor drugs and siRNA against ABCG2 were successfully delivered into CD133(+) cancer cells by loaded MSNs. Down-regulation of ABCG2 significantly enhanced the efficacy of chemotherapeutic drug-induced apoptosis in laryngeal carcinoma cells. Furthermore, the chemotherapeutic drug and siRNA loaded nanoparticles inhibited tumor growth in vivo in a laryngeal cancer mouse model.

Indexed as

Laryngeal NeoplasmsNanoparticlesAC133 AntigenAnimalsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2Blotting, WesternCell Line, TumorDrug CarriersDrug Delivery SystemsDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleFlow CytometryGene Knockdown TechniquesHumansABCG2 protein, humanAC133 AntigenAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily G, Member 2Drug CarriersNeoplasm ProteinsPROM1 protein, humanRNA, Small InterferingSilicon DioxideABCG2CD133+Laryngeal carcinomasiRNA nanoparticle

Identifiers

PMID26353857
OpenAlexW2197784381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.